FDA Approves Crenessity for Treating Classic Congenital Adrenal Hyperplasia
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH) in patients aged four and older. …
FDA Approves Crenessity for Treating Classic Congenital Adrenal Hyperplasia Read More